X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-three-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302110096.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-to-present-multiple-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302080292.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-st101-clinical-data-and-st316-preclinical-data-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-301956237.html
https://www.clinicaltrialsarena.com/news/sapience-st316-solid-tumours/
https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-its-first-in-class--catenin-antagonist-st316-in-advanced-solid-tumors-301849508.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-to-present-late-breaking-data-on-st101-and-st316-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023-301797273.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-late-breaking-research-poster-presentations-on-st101-and-st316-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023-301773763.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-receives-ind-clearance-from-fda-to-proceed-with-phase-1-2-study-of-st316-in-patients-with-solid-tumors-301771021.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-data-on-the-immune-activating-function-of-st101-at-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting-301674329.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-poster-presentation-on-the-immune-activating-function-of-st101-at-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting-301647214.html
Market Place
Share 
